Lupin Limited (LUPIN) — Board Meeting | 20 August 2025

· NSE 🟡 Notable Neutral
By StockFin Research Team AI-Assisted Analysis Source: BSE/NSE Filings

Lupin's Board approved the re-appointment of Mark D. McDade as an Independent Director for a second term of five years from January 28, 2026 to January 27, 2031, subject to shareholder approval. McDade brings over four decades of biopharmaceutical industry experience with expertise in governance, manufacturing, supply chain, and M&A. He holds degrees from Dartmouth College and Harvard Business School, and is not related to any existing directors or promoters.

📄 View Original Announcement (PDF)

About Lupin Limited (LUPIN)

Healthcare · Pharmaceuticals & Biotechnology · Listed on NSE

Market Cap: ₹1,04,071.47 Cr P/E: 36.2

View full LUPIN stock details →

📡 Get AI alerts when LUPIN files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track LUPIN — Free

📊 More LUPIN filings

See all LUPIN filings →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when LUPIN files new disclosures

Track LUPIN filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track LUPIN — Free

Free account · 2 AI queries/day